Small Cell Lung Cancer: Emerging Targets and Strategies for Precision Therapy
Abstract
:Simple Summary
Abstract
1. Introduction
2. Oncogenic Drivers and Targeted Therapy in SCLC
2.1. Antiangiogenic Agents
2.2. DNA-Damaging Agents
2.3. DLL3 Trials
2.4. Epigenetic Therapeutics
2.5. Novel Antibody–Drug Conjugates
2.6. Other Possible Therapies
2.7. Characterization of SCLC Subtypes
3. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- Lewis, D.R.; Check, D.P.; Caporaso, N.E.; Travis, W.D.; Devesa, S.S. US Lung Cancer Trends by Histologic Type. Cancer 2014, 120, 2883–2892. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Park, J.Y.; Jang, S.H. Epidemiology of Lung Cancer in Korea: Recent Trends. Tuberc. Respir. Dis. 2016, 79, 58–69. [Google Scholar] [CrossRef]
- Torre, L.A.; Siegel, R.L.; Jemal, A. Lung Cancer Statistics. Adv. Exp. Med. Biol. 2016, 893, 1–19. [Google Scholar] [CrossRef] [PubMed]
- Lung Cancer Survival Rates|5-Year Survival Rates for Lung Cancer. Available online: https://www.cancer.org/cancer/types/lung-cancer/detection-diagnosis-staging/survival-rates.html (accessed on 18 June 2023).
- Rudin, C.M.; Brambilla, E.; Faivre-Finn, C.; Sage, J. Small-Cell Lung Cancer. Nat. Rev. Dis. Primers 2021, 7. [Google Scholar] [CrossRef]
- Varghese, A.M.; Zakowski, M.F.; Yu, H.A.; Won, H.H.; Riely, G.J.; Krug, L.M.; Kris, M.G.; Rekhtman, N.; Ladanyi, M.; Wang, L.; et al. Small-Cell Lung Cancers in Patients Who Never Smoked Cigarettes. J. Thorac. Oncol. 2014, 9, 892–896. [Google Scholar] [CrossRef] [Green Version]
- El Sayed, R.; Blais, N. Immunotherapy in Extensive-Stage Small Cell Lung Cancer. Curr. Oncol. 2021, 28, 4093–4108. [Google Scholar] [CrossRef]
- Paz-Ares, L.; Chen, Y.; Reinmuth, N.; Hotta, K.; Trukhin, D.; Statsenko, G.; Hochmair, M.J.; Özgüroğlu, M.; Ji, J.H.; Garassino, M.C.; et al. Durvalumab, with or without Tremelimumab, plus Platinum-Etoposide in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer: 3-Year Overall Survival Update from CASPIAN. ESMO Open 2022, 7, 100408. [Google Scholar] [CrossRef]
- Ardizzoni, A.; Hansen, H.; Dombernowsky, P.; Gamucci, T.; Kaplan, S.; Postmus, P.; Giaccone, G.; Schaefer, B.; Wanders, J.; Verweij, J. Topotecan, a New Active Drug in the Second-Line Treatment of Small-Cell Lung Cancer: A Phase II Study in Patients with Refractory and Sensitive Disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J. Clin. Oncol. 1997, 15, 2090–2096. [Google Scholar] [CrossRef]
- Eckardt, J.R.; Von Pawel, J.; Pujol, J.L.; Papai, Z.; Quoix, E.; Ardizzoni, A.; Poulin, R.; Preston, A.J.; Dane, G.; Ross, G. Phase III Study of Oral Compared with Intravenous Topotecan as Second-Line Therapy in Small-Cell Lung Cancer. J. Clin. Oncol. 2007, 25, 2086–2092. [Google Scholar] [CrossRef]
- Trigo, J.; Subbiah, V.; Besse, B.; Moreno, V.; López, R.; Sala, M.A.; Peters, S.; Ponce, S.; Fernández, C.; Alfaro, V.; et al. Lurbinectedin as Second-Line Treatment for Patients with Small-Cell Lung Cancer: A Single-Arm, Open-Label, Phase 2 Basket Trial. Lancet Oncol. 2020, 21, 645–654. [Google Scholar] [CrossRef]
- Clinical Trial of Lurbinectedin as Single-Agent or in Combination with Irinotecan Versus Topotecan or Irinotecan in Patients with Relapsed Small-Cell Lung Cancer (LAGOON)—Full Text View—ClinicalTrials.gov. Available online: https://clinicaltrials.gov/ct2/show/NCT05153239 (accessed on 19 June 2023).
- Mosele, F.; Remon, J.; Mateo, J.; Westphalen, C.B.; Barlesi, F.; Lolkema, M.P.; Normanno, N.; Scarpa, A.; Robson, M.; Meric-Bernstam, F.; et al. Recommendations for the Use of Next-Generation Sequencing (NGS) for Patients with Metastatic Cancers: A Report from the ESMO Precision Medicine Working Group. Ann. Oncol. 2020, 31, 1491–1505. [Google Scholar] [CrossRef] [PubMed]
- Patel, A.S.; Yoo, S.; Kong, R.; Sato, T.; Sinha, A.; Karam, S.; Bao, L.; Fridrikh, M.; Emoto, K.; Nudelman, G.; et al. Prototypical Oncogene Family Myc Defines Unappreciated Distinct Lineage States of Small Cell Lung Cancer. Sci. Adv. 2021, 7, eabc2578. [Google Scholar] [CrossRef]
- Gu, J.; Zhou, Y.; Huang, L.; Ou, W.; Wu, J.; Li, S.; Xu, J.; Feng, J.; Liu, B. TP53 Mutation Is Associated with a Poor Clinical Outcome for Non-Small Cell Lung Cancer: Evidence from a Meta-Analysis. Mol. Clin. Oncol. 2016, 5, 705–713. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Patton, J.F.; Spigel, D.R.; Greco, F.A.; Liggett, W.H.; Zubkus, J.D.; Baskette, M.; Schreeder, M.; Woytowitz, D.; Nelson, E.; Hainsworth, J.D. Irinotecan (I), Carboplatin (C), and Radiotherapy (RT) Followed by Maintenance Bevacizumab (B) in the Treatment (Tx) of Limited-Stage Small Cell Lung Cancer (LS-SCLC): Update of a Phase II Trial of the Minnie Pearl Cancer Research Network. J. Clin. Oncol. 2006, 24 (Suppl. S18), 7085. [Google Scholar] [CrossRef]
- Spigel, D.R.; Hainsworth, J.D.; Yardley, D.A.; Raefsky, E.; Patton, J.; Peacock, N.; Farley, C.; Burris, H.A.; Greco, F.A. Tracheoesophageal Fistula Formation in Patients with Lung Cancer Treated with Chemoradiation and Bevacizumab. J. Clin. Oncol. 2010, 28, 43–48. [Google Scholar] [CrossRef]
- Pujol, J.L.; Lavole, A.; Quoix, E.; Molinier, O.; Souquet, P.J.; Barlesi, F.; Le Caer, H.; Moro-Sibilot, D.; Fournel, P.; Oster, J.P.; et al. Randomized Phase II-III Study of Bevacizumab in Combination with Chemotherapy in Previously Untreated Extensive Small-Cell Lung Cancer: Results from the IFCT-0802 Trial. Ann. Oncol. 2015, 26, 908–914. [Google Scholar] [CrossRef]
- Jalal, S.; Bedano, P.; Einhorn, L.; Bhatia, S.; Ansari, R.; Bechar, N.; Koneru, K.; Govindan, R.; Wu, J.; Yu, M.; et al. Paclitaxel plus Bevacizumab in Patients with Chemosensitive Relapsed Small Cell Lung Cancer: A Safety, Feasibility, and Efficacy Study from the Hoosier Oncology Group. J. Thorac. Oncol. 2010, 5, 2008–2011. [Google Scholar] [CrossRef] [Green Version]
- Ready, N.E.; Pang, H.H.; Gu, L.; Otterson, G.A.; Thomas, S.P.; Miller, A.A.; Baggstrom, M.; Masters, G.A.; Graziano, S.L.; Crawford, J.; et al. Chemotherapy with or without Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II Study—CALGB 30504 (Alliance). J. Clin. Oncol. 2015, 33, 1660–1665. [Google Scholar] [CrossRef]
- Allen, J.W.; Moon, J.; Redman, M.; Gadgeel, S.M.; Kelly, K.; Mack, P.C.; Saba, H.M.; Mohamed, M.K.; Jahanzeb, M.; Gandara, D.R. Southwest Oncology Group S0802: A Randomized, Phase II Trial of Weekly Topotecan with and without Ziv-Aflibercept in Patients with Platinum-Treated Small-Cell Lung Cancer. J. Clin. Oncol. 2014, 32, 2463–2470. [Google Scholar] [CrossRef] [Green Version]
- Russo, A.E.; Priolo, D.; Antonelli, G.; Libra, M.; McCubrey, J.A.; Ferraù, F. Bevacizumab in the Treatment of NSCLC: Patient Selection and Perspectives. Lung Cancer Targets Ther. 2017, 8, 259–269. [Google Scholar] [CrossRef] [Green Version]
- Hellmann, M.D.; Callahan, M.K.; Awad, M.M.; Calvo, E.; Ascierto, P.A.; Atmaca, A.; Rizvi, N.A.; Hirsch, F.R.; Selvaggi, G.; Szustakowski, J.D.; et al. Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer. Cancer Cell 2018, 33, 853–861.e4. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cheng, Y.; Li, H.; Liu, Y.; Ma, L.; Liu, X.; Liu, Y.; Liu, J.; Zhang, S. Distribution and Clinical Significance of CTLA4, PD-1 and PD-L1 in Peripheral Blood of Patients with Small-Cell Lung Cancer. J. Clin. Oncol. 2015, 33 (Suppl. S15), 7574. [Google Scholar] [CrossRef]
- Yamane, H.; Isozaki, H.; Takeyama, M.; Ochi, N.; Kudo, K.; Honda, Y.; Yamagishi, T.; Kubo, T.; Kiura, K.; Takigawa, N. Programmed Cell Death Protein 1 and Programmed Death-Ligand 1 Are Expressed on the Surface of Some Small-Cell Lung Cancer Lines. Am. J. Cancer Res. 2015, 5, 1553–1557. [Google Scholar] [PubMed]
- Majem, M.; Rudin, C.M. Small-Cell Lung Cancer in the Era of Immunotherapy. Transl. Lung Cancer Res. 2017, 6 (Suppl. 1), S67. [Google Scholar] [CrossRef] [Green Version]
- Chatzinikolaou, G.; Karakasilioti, I.; Garinis, G.A. DNA Damage and Innate Immunity: Links and Trade-Offs. Trends Immunol. 2014, 35, 429–435. [Google Scholar] [CrossRef]
- Pietanza, M.C.; Waqar, S.N.; Krug, L.M.; Dowlati, A.; Hann, C.L.; Chiappori, A.; Owonikoko, T.K.; Woo, K.M.; Cardnell, R.J.; Fujimoto, J.; et al. Randomized, Double-Blind, Phase II Study of Temozolomide in Combination with Either Veliparib or Placebo in Patients with Relapsed-Sensitive or Refractory Small-Cell Lung Cancer. J. Clin. Oncol. 2018, 36, 2386–2394. [Google Scholar] [CrossRef] [PubMed]
- Farago, A.; Yeap, B.; Heist, R.; Marcoux, J.P.; Rangachari, D.; Barbie, D.; Kennedy, E.; Mino-Kenudson, M.; Shaw, A. OA15.01 Combination Olaparib and Temozolomide in Relapsed Small Cell Lung Cancer: Updated Results from Phase 1/2 Clinical Trial. J. Thorac. Oncol. 2019, 14, S246. [Google Scholar] [CrossRef]
- Goldman, J.W.; Cummings, A.L.; Mendenhall, M.A.; Velez, M.A.; Babu, S.; Johnson, T.T.; Alcantar, J.M.; Dakhil, S.R.; Kanamori, D.E.; Lawler, W.E.; et al. Primary Analysis from the Phase 2 Study of Continuous Talazoparib (TALA) plus Intermittent Low-Dose Temozolomide (TMZ) in Patients with Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer (ES-SCLC). J. Clin. Oncol. 2022, 40 (Suppl. S16), 8517. [Google Scholar] [CrossRef]
- Winkler, C.; Armenia, J.; Jones, G.N.; Tobalina, L.; Sale, M.J.; Petreus, T.; Baird, T.; Serra, V.; Wang, A.T.; Lau, A.; et al. SLFN11 Informs on Standard of Care and Novel Treatments in a Wide Range of Cancer Models. Br. J. Cancer 2021, 124, 951–962. [Google Scholar] [CrossRef]
- Abdel Karim, N.F.; Miao, J.; Reckamp, K.L.; Gay, C.M.; Byers, L.A.; Zhao, Y.; Redman, M.W.; Carrizosa, D.R.; Wang, W.-L.; Petty, W.J.; et al. SWOG S1929: Phase II Randomized Study of Maintenance Atezolizumab (A) versus Atezolizumab + Talazoparib (AT) in Patients with SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC). J. Clin. Oncol. 2023, 41 (Suppl. S16), 8504. [Google Scholar] [CrossRef]
- Farago, A.F.; Yeap, B.Y.; Stanzione, M.; Hung, Y.P.; Heist, R.S.; Marcoux, J.P.; Zhong, J.; Rangachari, D.; Barbie, D.A.; Phat, S.; et al. Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer. Cancer Discov. 2019, 9, 1372–1387. [Google Scholar] [CrossRef] [Green Version]
- de Bono, J.; Ramanathan, R.K.; Mina, L.; Chugh, R.; Glaspy, J.; Rafii, S.; Kaye, S.; Sachdev, J.; Heymach, J.; Smith, D.C.; et al. Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers. Cancer Discov. 2017, 7, 620–629. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Owonikoko, T.K.; Dahlberg, S.E.; Sica, G.L.; Wagner, L.I.; Wade, J.L.; Srkalovic, G.; Lash, B.W.; Leach, J.W.; Leal, T.B.; Aggarwal, C.; et al. Randomized Phase II Trial of Cisplatin and Etoposide in Combination with Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study. J. Clin. Oncol. 2019, 37, 222–229. [Google Scholar] [CrossRef]
- Sen, T.; Gay, C.M.; Byers, L.A. Targeting DNA Damage Repair in Small Cell Lung Cancer and the Biomarker Landscape. Transl. Lung Cancer Res. 2018, 7, 50–68. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhang, Y.; Hunter, T. Roles of Chk1 in Cell Biology and Cancer Therapy. Int. J. Cancer 2014, 134, 1013–1023. [Google Scholar] [CrossRef] [Green Version]
- Gadhikar, M.A.; Sciuto, M.R.; Alves, M.V.O.; Pickering, C.R.; Osman, A.A.; Neskey, D.M.; Zhao, M.; Fitzgerald, A.L.; Myers, J.N.; Frederick, M.J. Chk1/2 Inhibition Overcomes the Cisplatin Resistance of Head and Neck Cancer Cells Secondary to the Loss of Functional P53. Mol. Cancer Ther. 2013, 12, 1860–1873. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sen, T.; Tong, P.; Stewart, C.A.; Cristea, S.; Valliani, A.; Shames, D.S.; Redwood, A.B.; Fan, Y.H.; Li, L.; Glisson, B.S.; et al. CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib. Cancer Res. 2017, 77, 3870–3884. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Byers, L.A.; Navarro, A.; Schaefer, E.; Johnson, M.; Özgüroğlu, M.; Han, J.Y.; Bondarenko, I.; Cicin, I.; Dragnev, K.H.; Abel, A.; et al. A Phase II Trial of Prexasertib (LY2606368) in Patients With Extensive-Stage Small-Cell Lung Cancer. Clin. Lung Cancer 2021, 22, 531–540. [Google Scholar] [CrossRef]
- Cui, M.; Augert, A.; Rongione, M.; Conkrite, K.; Parazzoli, S.; Nikitin, A.Y.; Ingolia, N.; MacPherson, D. PTEN Is a Potent Suppressor of Small Cell Lung Cancer. Mol. Cancer Res. 2014, 12, 654–659. [Google Scholar] [CrossRef] [Green Version]
- Lim, J.S.; Ibaseta, A.; Fischer, M.M.; Cancilla, B.; O’Young, G.; Cristea, S.; Luca, V.C.; Yang, D.; Jahchan, N.S.; Hamard, C.; et al. Intratumoral Heterogeneity Generated by Notch Signaling Promotes Small Cell Lung Cancer. Nature 2017, 545, 360. [Google Scholar] [CrossRef] [Green Version]
- Rojo, F.; Corassa, M.; Mavroudis, D.; Öz, A.B.; Biesma, B.; Brcic, L.; Pauwels, P.; Sailer, V.; Gosney, J.; Miljkovic, D.; et al. International Real-World Study of DLL3 Expression in Patients with Small Cell Lung Cancer. Lung Cancer 2020, 147, 237–243. [Google Scholar] [CrossRef] [PubMed]
- Tanaka, K.; Isse, K.; Fujihira, T.; Takenoyama, M.; Saunders, L.; Bheddah, S.; Nakanishi, Y.; Okamoto, I. Prevalence of Delta-like Protein 3 Expression in Patients with Small Cell Lung Cancer. Lung Cancer 2018, 115, 116–120. [Google Scholar] [CrossRef] [PubMed]
- Furuta, M.; Kikuchi, H.; Shoji, T.; Takashima, Y.; Kikuchi, E.; Kikuchi, J.; Kinoshita, I.; Dosaka-Akita, H.; Sakakibara-Konishi, J. DLL3 Regulates the Migration and Invasion of Small Cell Lung Cancer by Modulating Snail. Cancer Sci. 2019, 110, 1599–1608. [Google Scholar] [CrossRef] [Green Version]
- Owen, D.H.; Giffin, M.J.; Bailis, J.M.; Smit, M.A.D.; Carbone, D.P.; He, K. DLL3: An Emerging Target in Small Cell Lung Cancer. J. Hematol. Oncol. 2019, 12, 61. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Blackhall, F.; Jao, K.; Greillier, L.; Cho, B.C.; Penkov, K.; Reguart, N.; Majem, M.; Nackaerts, K.; Syrigos, K.; Hansen, K.; et al. Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results from the Phase 3 TAHOE Study. J. Thorac. Oncol. 2021, 16, 1547–1558. [Google Scholar] [CrossRef]
- Johnson, M.L.; Dy, G.K.; Mamdani, H.; Dowlati, A.; Schoenfeld, A.J.; Pacheco, J.M.; Sanborn, R.E.; Menon, S.P.; Santiago, L.; Yaron, Y.; et al. Interim Results of an Ongoing Phase 1/2a Study of HPN328, a Tri-Specific, Half-Life Extended, DLL3-Targeting, T-Cell Engager, in Patients with Small Cell Lung Cancer and Other Neuroendocrine Cancers. J. Clin. Oncol. 2022, 40 (Suppl. S16), 8566. [Google Scholar] [CrossRef]
- Wermke, M.; Felip, E.; Kuboki, Y.; Morgensztern, D.; Sayehli, C.; Sanmamed, M.F.; Arriola, E.; Oum’Hamed, Z.; Song, E.; Studeny, M.; et al. First-in-Human Dose-Escalation Trial of BI 764532, a Delta-like Ligand 3 (DLL3)/CD3 IgG-like T-Cell Engager in Patients (Pts) with DLL3-Positive (DLL3+) Small-Cell Lung Cancer (SCLC) and Neuroendocrine Carcinoma (NEC). J. Clin. Oncol. 2023, 41 (Suppl. S16), 8502. [Google Scholar] [CrossRef]
- Wermke, M.; Felip, E.; Gambardella, V.; Kuboki, Y.; Morgensztern, D.; Hamed, Z.O.; Liu, M.; Studeny, M.; Owonikoko, T.K. Phase i Trial of the DLL3/CD3 Bispecific T-Cell Engager BI 764532 in DLL3-Positive Small-Cell Lung Cancer and Neuroendocrine Carcinomas. Future Oncol. 2022, 18, 2639–2649. [Google Scholar] [CrossRef]
- Paz-Ares, L.; Champiat, S.; Lai, W.V.; Izumi, H.; Govindan, R.; Boyer, M.; Hummel, H.-D.; Borghaei, H.; Johnson, M.L.; Steeghs, N.; et al. Tarlatamab, a First-In-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small Cell Lung Cancer: An Open-Label, Phase I Study. J. Clin. Oncol. 2023, 41, 2893–2903. [Google Scholar] [CrossRef]
- Byers, L.; Heymach, J.; Gibbons, D.; Zhang, J.; Chiappori, A.; Rasmussen, E.; Decato, B.; Smit, M.-A.; Sadraei, N.H. 697 A Phase 1 Study of AMG 119, a DLL3-Targeting, Chimeric Antigen Receptor (CAR) T Cell Therapy, in Relapsed/Refractory Small Cell Lung Cancer (SCLC). J. ImmunoTher. Cancer 2022, 10. [Google Scholar] [CrossRef]
- Chen, J.; Pan, X.; Na, F.; Chen, X.; Chen, C. Epigenetic Reprogramming in Small Cell Lung Cancer. Cancer Biol. Med. 2022, 19, 111–1116. [Google Scholar] [CrossRef] [PubMed]
- Murai, F.; Koinuma, D.; Shinozaki-Ushiku, A.; Fukayama, M.; Miyaozono, K.; Ehata, S. EZH2 Promotes Progression of Small Cell Lung Cancer by Suppressing the TGF-β-Smad-ASCL1 Pathway. Cell Discov. 2015, 1, 15026. [Google Scholar] [CrossRef] [PubMed]
- Augert, A.; Eastwood, E.; Ibrahim, A.H.; Wu, N.; Grunblatt, E.; Basom, R.; Liggitt, D.; Eaton, K.D.; Martins, R.; Poirier, J.T.; et al. Targeting NOTCH Activation in Small Cell Lung Cancer through LSD1 Inhibition. Sci. Signal 2019, 12, eaau2922. [Google Scholar] [CrossRef]
- Hiatt, J.B.; Sandborg, H.; Garrison, S.M.; Arnold, H.U.; Liao, S.Y.; Norton, J.P.; Friesen, T.J.; Wu, F.; Sutherland, K.D.; Rienhoff, H.Y.; et al. Inhibition of LSD1 with Bomedemstat Sensitizes Small Cell Lung Cancer to Immune Checkpoint Blockade and T-Cell Killing. Clin. Cancer Res. 2022, 28, 4551–4564. [Google Scholar] [CrossRef]
- Bauer, T.M.; Besse, B.; Martinez-Marti, A.; Trigo, J.M.; Moreno, V.; Garrido, P.; Ferron-Brady, G.; Wu, Y.; Park, J.; Collingwood, T.; et al. Phase I, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2879552 in Relapsed/Refractory SCLC. J. Thorac. Oncol. 2019, 14, 1828–1838. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Thomas, A.; Teicher, B.A.; Hassan, R. Antibody–Drug Conjugates for Cancer Therapy. Lancet Oncol. 2016, 17, e254–e262. [Google Scholar] [CrossRef]
- Bardia, A.; Messersmith, W.A.; Kio, E.A.; Berlin, J.D.; Vahdat, L.; Masters, G.A.; Moroose, R.; Santin, A.D.; Kalinsky, K.; Picozzi, V.; et al. Sacituzumab Govitecan, a Trop-2-Directed Antibody-Drug Conjugate, for Patients with Epithelial Cancer: Final Safety and Efficacy Results from the Phase I/II IMMU-132-01 Basket Trial. Ann. Oncol. 2021, 32, 746–756. [Google Scholar] [CrossRef]
- DS-7300 Continues to Show Promising Durable Response in Patients with Several Types of Advanced Cancer—Daiichi Sankyo US. Available online: https://daiichisankyo.us/press-releases/-/article/ds-7300-continues-to-show-promising-durable-response-in-patients-with-several-types-of-advanced-cancer (accessed on 14 June 2023).
- Morgensztern, D.; Ready, N.E.; Johnson, M.L.; Dowlati, A.; Choudhury, N.J.; Carbone, D.P.; Schaefer, E.S.; Arnold, S.M.; Puri, S.; Piotrowska, Z.; et al. First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6 (SEZ6)–Targeting Antibody-Drug Conjugate, in Patients with Small Cell Lung Cancer. J. Clin. Oncol. 2023, 41 (Suppl. S16), 3002. [Google Scholar] [CrossRef]
- Inamura, K.; Yokouchi, Y.; Kobayashi, M.; Ninomiya, H.; Sakakibara, R.; Subat, S.; Nagano, H.; Nomura, K.; Okumura, S.; Shibutani, T.; et al. Association of Tumor TROP2 Expression with Prognosis Varies among Lung Cancer Subtypes. Oncotarget 2017, 8, 28725–28735. [Google Scholar] [CrossRef]
- Study of Sacituzumab Govitecan in Participants with Metastatic Solid Tumors—Full Text View—ClinicalTrials.gov. Available online: https://clinicaltrials.gov/ct2/show/NCT03964727 (accessed on 19 June 2023).
- Ifinatamab Deruxtecan (I-DXd) in Subjects with Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)—Full Text View—ClinicalTrials.gov. Available online: https://clinicaltrials.gov/ct2/show/NCT05280470 (accessed on 14 June 2023).
- Wiedemeyer, W.R.; Gavrilyuk, J.; Schammel, A.; Zhao, X.; Sarvaiya, H.; Pysz, M.; Gu, C.; You, M.; Isse, K.; Sullivan, T.; et al. ABBV-011, A Novel, Calicheamicin-Based Antibody–Drug Conjugate, Targets SEZ6 to Eradicate Small Cell Lung Cancer Tumors. Mol. Cancer Ther. 2022, 21, 986–998. [Google Scholar] [CrossRef]
- Vollmar, B.S.; Frantz, C.; Schutten, M.M.; Zhong, F.; del Rosario, G.; Go, M.A.T.; Yu, S.F.; Leipold, D.D.; Kamath, A.V.; Ng, C.; et al. Calicheamicin Antibody-Drug Conjugates with Improved Properties. Mol. Cancer Ther. 2021, 20, 1112–1120. [Google Scholar] [CrossRef] [PubMed]
- Morgensztern, D.; Besse, B.; Greillier, L.; Santana-Davila, R.; Ready, N.; Hann, C.L.; Glisson, B.S.; Farago, A.F.; Dowlati, A.; Rudin, C.M.; et al. Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results from the Phase II TrINITY Study. Clin. Cancer Res. 2019, 25, 6958–6966. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhang, S.; Cordon-Cardo, C.; Zhang, H.S.; Reuter, V.E.; Adluri, S.; Hamilton, W.B.; Lloyd, K.O.; Livingiston, P.O. Selection of Tumor Antigens as Targets for Immune Attack Using Immunohistochemistry: I. Focus on Gangliosides. Int. J. Cancer 1997, 73, 42–49. [Google Scholar] [CrossRef]
- Chu, Q.; Leighl, N.B.; Surmont, V.; van Herpen, C.; Sibille, A.; Markman, B.; Clarke, S.; Juergens, R.A.; Rivera, M.A.; Andelkovic, V.; et al. BMS-986012, an Anti–Fucosyl-GM1 Monoclonal Antibody as Monotherapy or in Combination With Nivolumab in Relapsed/Refractory SCLC: Results From a First-in-Human Phase 1/2 Study. JTO Clin. Res. Rep. 2022, 3, 100400. [Google Scholar] [CrossRef]
- Sun, B.; Mason, S.; Wilson, R.C.; Hazard, S.E.; Wang, Y.; Fang, R.; Wang, Q.; Yeh, E.S.; Yang, M.; Roberts, T.M.; et al. Inhibition of the Transcriptional Kinase CDK7 Overcomes Therapeutic Resistance in HER2-Positive Breast Cancers. Oncogene 2020, 39, 50–63. [Google Scholar] [CrossRef] [Green Version]
- Christensen, C.L.; Kwiatkowski, N.; Abraham, B.J.; Carretero, J.; Al-Shahrour, F.; Zhang, T.; Chipumuro, E.; Herter-Sprie, G.S.; Akbay, E.A.; Altabef, A.; et al. Targeting Transcriptional Addictions in Small Cell Lung Cancer with a Covalent CDK7 Inhibitor. Cancer Cell 2014, 26, 909–922. [Google Scholar] [CrossRef] [Green Version]
- Slotman, B.J.; Van Tinteren, H.; Praag, J.O.; Knegjens, J.L.; El Sharouni, S.Y.; Hatton, M.; Keijser, A.; Faivre-Finn, C.; Senan, S. Use of Thoracic Radiotherapy for Extensive Stage Small-Cell Lung Cancer: A Phase 3 Randomised Controlled Trial. Lancet 2015, 385, 36–42. [Google Scholar] [CrossRef]
- Nishiga, Y.; Drainas, A.P.; Baron, M.; Bhattacharya, D.; Barkal, A.A.; Ahrari, Y.; Mancusi, R.; Ross, J.B.; Takahashi, N.; Thomas, A.; et al. Radiotherapy in Combination with CD47 Blockade Elicits a Macrophage-Mediated Abscopal Effect. Nat. Cancer 2022, 3, 1351–1366. [Google Scholar] [CrossRef] [PubMed]
- Rudin, C.M.; Poirier, J.T.; Byers, L.A.; Dive, C.; Dowlati, A.; George, J.; Heymach, J.V.; Johnson, J.E.; Lehman, J.M.; MacPherson, D.; et al. Molecular Subtypes of Small Cell Lung Cancer: A Synthesis of Human and Mouse Model Data. Nat. Rev. Cancer 2019, 19, 289–297. [Google Scholar] [CrossRef]
- Gay, C.M.; Stewart, C.A.; Park, E.M.; Diao, L.; Groves, S.M.; Heeke, S.; Nabet, B.Y.; Fujimoto, J.; Solis, L.M.; Lu, W.; et al. Patterns of Transcription Factor Programs and Immune Pathway Activation Define Four Major Subtypes of SCLC with Distinct Therapeutic Vulnerabilities. Cancer Cell 2021, 39, 346–360.e7. [Google Scholar] [CrossRef]
Topotecan [10] | Talazoparib + TMZ [30] | Olaparib + TMZ [33] | Veliparib + TMZ [28] | |
---|---|---|---|---|
n | 151 | 28 | 50 | 104 |
ORR | 21.9% | 39.3% | 41.7% | 39% |
Median DOR | 6.4 mo | 4.3 mo | 4.3 mo | 4.6 mo |
Median PFS | ND | 4.3 mo | 4.2 mo | 3.8 mo |
Median OS | 8.75 mo | 11.9 mo | 8.5 mo | 8.2 mo |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Patel, S.R.; Das, M. Small Cell Lung Cancer: Emerging Targets and Strategies for Precision Therapy. Cancers 2023, 15, 4016. https://doi.org/10.3390/cancers15164016
Patel SR, Das M. Small Cell Lung Cancer: Emerging Targets and Strategies for Precision Therapy. Cancers. 2023; 15(16):4016. https://doi.org/10.3390/cancers15164016
Chicago/Turabian StylePatel, Shruti R., and Millie Das. 2023. "Small Cell Lung Cancer: Emerging Targets and Strategies for Precision Therapy" Cancers 15, no. 16: 4016. https://doi.org/10.3390/cancers15164016
APA StylePatel, S. R., & Das, M. (2023). Small Cell Lung Cancer: Emerging Targets and Strategies for Precision Therapy. Cancers, 15(16), 4016. https://doi.org/10.3390/cancers15164016